ResMed Reports 10% Fiscal Revenue Growth, Raises Dividend

ResMed's Fiscal 2026 Outperformance Driven by Core Device Demand

ResMed Inc. ($RMD) posted a 10% increase in fiscal 2026 revenue, achieving $5.653 billion, a figure that not only met but surpassed analyst consensus expectations, primarily fueled by strong global demand for its sleep apnea and respiratory care devices. The medical device manufacturer simultaneously announced a substantial hike in its quarterly dividend, underscoring its robust financial health and commitment to shareholder returns. This strong performance marks a significant milestone for the company, solidifying its position in the competitive medical device sector.

Following the upbeat financial disclosure, $RMD shares responded positively, climbing 4.8% to $255.70 in pre-market trading, before settling at $254.85 at market open. This immediate investor reaction reflects optimism regarding the company's operational execution and its ability to capitalize on growing market needs for chronic respiratory conditions, particularly as global health awareness around sleep disorders continues to rise. The trading volume surged to 1.5 million shares within the first hour, significantly above its 30-day average of 950,000 shares.

Market Impact

The 4.8% jump in $RMD shares pushed the stock to its highest level since late March, nearing its 52-week high of $262.30. This upward movement added approximately $1.9 billion to ResMed's market capitalization, bringing it to an estimated $37.5 billion. The strong opening marked the largest single-day percentage gain for $RMD since October 2025, when the company provided an optimistic outlook for its connected care solutions.

This positive momentum for ResMed also had a ripple effect across the broader medical device sector. Competitors such as Koninklijke Philips NV ($PHG), which has faced challenges with product recalls in its sleep and respiratory care division, saw a modest 0.7% decline, as ResMed's strong results highlighted its market share gains. The iShares U.S. Medical Devices ETF ($IHI) also experienced a slight uptick of 0.3%, suggesting a generally favorable sentiment for the industry but with ResMed outperforming its peers due to its specific strong report. The robust demand for ResMed’s devices, particularly its CPAP machines and masks, indicates a continuing shift in market preferences and underscores the company’s effective product strategy and supply chain management.

What Analysts Are Saying

Analysts were largely positive on ResMed's fiscal 2026 performance, highlighting the company's consistent execution and strategic positioning. According to J.P. Morgan analyst Robbie Marcus, "ResMed's revenue beat of $73 million, coupled with a 12% EPS growth, demonstrates significant resilience and market capture, especially in light of ongoing competitive dynamics." Marcus further noted that "the strength in device sales, particularly in the Americas, confirms robust demand and effective commercial strategies, positioning $RMD for continued leadership in sleep and respiratory care."

RBC Capital Markets analyst Shagun Singh echoed this sentiment, emphasizing the dividend increase as a key indicator of financial health. "The 15% increase in the quarterly dividend to $0.50 per share signals strong free cash flow generation and management's confidence in sustainable long-term growth," Singh stated in a client note. "This move not only rewards shareholders but also reinforces ResMed's attractive investment profile in a high-growth healthcare segment." Singh also pointed to the company's expanding software-as-a-service (SaaS) revenue, which grew 8% to $510 million, as a diversification strength.

However, some analysts maintained a cautious stance on valuation. Citi analyst Joanne Wuensch acknowledged the strong results but suggested that "while ResMed's performance is commendable, the stock's current valuation at approximately 30 times forward earnings already prices in significant growth." Wuensch added, "Investors should monitor the pace of new product innovations and potential competitive responses to justify further multiple expansion, particularly as Philips aims to re-enter the market more aggressively post-recall."

What to Watch

Investors will be closely monitoring several key factors following ResMed's impressive fiscal 2026 results. The company's upcoming Q1 2027 earnings call, tentatively scheduled for late October, will provide crucial insights into its forward guidance for the new fiscal year. Specific attention will be paid to any updates on global supply chain stability and the impact of inflation on gross margins, which stood at 56.5% for fiscal 2026.

Technically, $RMD shares now face immediate resistance at the 52-week high of $262.30. A sustained break above this level could signal a stronger bullish trend. On the downside, the previous support level around $245 could act as a crucial psychological floor should any negative news emerge. Investors should also watch for any developments regarding competitor Philips' remediation efforts and potential re-entry into certain market segments, which could intensify competition in the respiratory care device market. Furthermore, any changes in regulatory reimbursement policies for sleep apnea diagnostics and therapies across major markets like the U.S. and Europe could influence future revenue streams.